half yearly out27 Aug 2021 11:00
We are increasingly optimistic about the potential new sales that can be realized with our channel partners and distributors and expect first half sales momentum to continue for the remainder of the current financial year. The primary drivers of shareholder value, however, will come from developments in our key strategic projects, IB Zero Gβ’, IB Rad Tech Automation, IB CADβ’ - "Detecting the Undetectable", IB Traxβ’ and the Phase I Clinical Trial for Oral Gallium Maltolate. The range of potential outcomes from these projects is now very wide and therefore impossible to predict. However, at the upper end of the range of outcomes, if achieved, the impact on shareholder value would be significant.